M516102

M516102 is a synthetic small molecule drug that was developed by Maruho Pharmaceutical for the treatment of atopic dermatitis and pruritus associated with atopic dermatitis. It reached Phase 2 clinical trials but development has since been discontinued. The precise mechanism of action remains unknown, and it does not represent a novel mechanistic class. The drug was administered orally in clinical studies targeting immune system diseases, congenital disorders, and skin/musculoskeletal diseases[1][2][4]. No adverse events or FDA designations have been reported in public sources.

Other names

Neurokinin-1 receptor antagonist (Maruho)NK-1 receptor antagonist (Maruho)